bimekizumab
General
Pronunciation:
bye-me-kiz-ue-mab
Trade Name(s)
- Bimzelx
Ther. Class.
antipsoriatics
Pharm. Class.
monoclonal antibodies
interleukin antagonists
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Bimekizumab." Davis's Drug Guide, 19th ed., F.A. Davis Company, 2024. Medicine Central, im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110965/4/bimekizumab.
Vallerand AHA, Sanoski CAC, Quiring CC. Bimekizumab. Davis's Drug Guide. F.A. Davis Company; 2024. https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110965/4/bimekizumab. Accessed December 26, 2024.
Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2024). Bimekizumab. In Davis's Drug Guide (19th ed.). F.A. Davis Company. https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110965/4/bimekizumab
Vallerand AHA, Sanoski CAC, Quiring CC. Bimekizumab [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2024. [cited 2024 December 26]. Available from: https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110965/4/bimekizumab.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - bimekizumab
ID - 110965
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - Quiring,Courtney,
BT - Davis's Drug Guide
UR - https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110965/4/bimekizumab
PB - F.A. Davis Company
ET - 19
DB - Medicine Central
DP - Unbound Medicine
ER -